This company has been acquired
Myovant Sciences Management
Management criteria checks 4/4
Key information
Dave Marek
Chief executive officer
US$6.2m
Total compensation
| CEO salary percentage | 12.00% |
| CEO tenure | 2.2yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28
Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | -US$184m |
| Sep 30 2022 | n/a | n/a | -US$190m |
| Jun 30 2022 | n/a | n/a | -US$166m |
| Mar 31 2022 | US$6m | US$750k | -US$206m |
| Dec 31 2021 | n/a | n/a | -US$228m |
| Sep 30 2021 | n/a | n/a | -US$238m |
| Jun 30 2021 | n/a | n/a | -US$284m |
| Mar 31 2021 | US$10m | US$151k | -US$255m |
Compensation vs Market: Dave's total compensation ($USD6.25M) is about average for companies of similar size in the US market ($USD6.53M).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Marek (57 yo)
Mr. David C. Marek, also known as Dave, has been Director of Myovant Sciences Ltd. since January 4, 2021 and served as its Principal Executive Officer. He had been Chief Commercial Officer of Axsome Therap...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
| Principal Financial Officer | 1.5yrs | US$5.16m | 0.021% $ 559.0k | |
| Chief Commercial Officer | 1.9yrs | US$3.47m | 0.022% $ 587.9k | |
| General Counsel & Corporate Secretary | 5.7yrs | US$2.83m | 0.36% $ 9.6m | |
| Director of Corporate Communications | no data | no data | no data | |
| Senior Vice President of Human Resources | less than a year | no data | no data | |
| Senior Vice President of Product Development | 6.6yrs | no data | no data | |
| Chief Medical Officer | 5.7yrs | US$1.98m | 0.089% $ 2.3m | |
| Head of Drug Safety & Pharmacovigilance | 5.7yrs | no data | no data | |
| Senior VP of Pharmaceutical Operations & Development | 4.3yrs | no data | no data |
Experienced Management: MYOV's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
| Chairman of the Board | 4.5yrs | US$376.79k | 0% $ 0 | |
| Independent Director | 6.3yrs | US$363.33k | 0% $ 0 | |
| Director | 3.3yrs | US$341.79k | 0% $ 0 | |
| Lead Independent Director | 4.7yrs | US$369.95k | 0% $ 0 | |
| Non Independent Director | less than a year | no data | no data | |
| Independent Director | 1.3yrs | US$567.05k | 0% $ 0 |
Experienced Board: MYOV's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/12 03:05 |
| End of Day Share Price | 2023/03/09 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Myovant Sciences Ltd. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Mohit Bansal | Citigroup Inc |
| Jason Butler | Citizens JMP Securities, LLC |